EPRX vs PACB vs IRWD vs PTGX vs NKTR

For growth investors, Pacific Biosciences of California, Inc.

(PACB) is the stronger pick with 3. 9% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Ironwood Pharmaceuticals, Inc. (IRWD) offers the better valuation at 28. 1x trailing P/E (3. 1x forward), making it the more compelling value choice. Analysts rate Eupraxia Pharmaceuticals Inc. (EPRX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Ironwood Pharmaceuticals, Inc.

is actually cheaper at 3. 1x.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +251. 2%, compared to -93. 9% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: PTGX returned +749. 2% versus PACB's -84. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 23β versus Ironwood Pharmaceuticals, Inc. 's 2. 62β — meaning IRWD is approximately 1028% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Eupraxia Pharmaceuticals Inc. (EPRX) carries a lower debt/equity ratio of 0% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pacific Biosciences of California, Inc.

(PACB) is pulling ahead at 3. 9% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Nektar Therapeutics grew EPS -12. 1% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ironwood Pharmaceuticals, Inc.

(IRWD) is the more profitable company, earning 8. 1% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus -348. 5% for PACB. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Ironwood Pharmaceuticals, Inc.

(IRWD) trades at 3. 1x forward P/E versus 25. 8x for Protagonist Therapeutics, Inc. — 22. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EPRX: 155. 0% to $19. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +749. 2% 10Y return). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTGX: +749. 2%, PACB: -84. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.